All data are based on the daily closing price as of July 17, 2024
o

Oscotec

039200.KQ
30.92 USD
-0.44
-1.40%

Overview

Last close
30.92 usd
Market cap
868.84M usd
52 week high
31.92 usd
52 week low
13.32 usd
Target price
30.12 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
218.9439
Price/Book Value
10.8973
Enterprise Value
715.47M usd
EV/Revenue
199.1176
EV/EBITDA
-32.8386

Key financials

Revenue TTM
3.52M usd
Gross Profit TTM
1.28M usd
EBITDA TTM
-18.62M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
93.38M usd
Net debt
N/A usd

About

Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody, which is in preclinical Phase for the treatment of Alzheimer's disease. The company also offers dental health products, such as bone graft comprising InduCera, BioCera-F, and SynCeraII; and membrane consisting of LysoGide and CollaGuide. In addition, it provides functional ingredients comprises OPB for osteoporosis; AIF for arthritis; SGA that enhance bone growth; and PRF-K for perio diseases. The company was formerly known as Oscotec Co., Ltd and changed its name to Oscotec Inc. in June 1999. Oscotec Inc. was founded in 1988 and is based in Seongnam, South Korea.
  • Symbol
    039200.KQ
  • Exchange
    KQ
  • Isin
    KR7039200001
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Pharmaceuticals
  • CEO
    Mr. Jeung-Keun Kim
  • Headquarter
    Seongnam-si
  • Web site
    https://www.oscotec.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top